Development status: Approved, off-patent

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Binds to bacterial penicillin-binding proteins (PBP) and interferes with bacterial cell wall integrity and synthesis. Active against Gram-negative bacteria but vulnerable to higher levels of extended-spectum beta-lactamases (ESBL) and high resistance rates in Pseudomonas aeruginosa

Additional information: Semisynthetic Cephalosporine, derived from Cephalosporin C. Fixed combination with several beta-lactamase inhibitors (taniborbactam, zidebactam, enmetazobactam, tazobactam)